To date, six CAR T therapies have received FDA approval: four targeting CD19 (tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel, and brexucabtagene autoleucel) and two targeting BCMA (idecabtagene vicleucel and ciltacabtagene autoleucel) for multiple myeloma (Mitra et al., 2023). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.